Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328368 | 0.87 | HSP90AA1 (0.32) | HSP90AA1JAK1JAK3 | |
| SCHEMBL1075315 | 0.83 | HSP90AA1 (0.33) | HSP90AA1JAK1JAK3 | |
| SCHEMBL1082183 | 0.81 | JAK1 (0.34) | HSP90AA1JAK1JAK3 | |
| SCHEMBL10328032 | 0.81 | HSP90AA1 (0.39) | HSP90AA1JAK1JAK3 | |
| SCHEMBL10327978 | 0.79 | PIK3CA (0.32) | — | |
| SCHEMBL1074595 | 0.79 | JAK1 (0.33) | HSP90AA1JAK1JAK3 | |
| SCHEMBL583583 | 0.76 | HDAC1 (0.39) | — | |
| SCHEMBL1074594 | 0.75 | HSP90AA1 (0.32) | HSP90AA1JAK1JAK3 | |
| SCHEMBL1023161 | 0.75 | HSP90AA1 (0.34) | HSP90AA1JAK1JAK3 | |
| SCHEMBL1082625 | 0.73 | PIK3CA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | HSP90AA1 2279/4885JAK1 1133/4885JAK3 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.